LCS has entered a market varyingly referred to as sequence capture, target enrichment, and sequence enrichment. While the firms playing in this application area cannot agree on a name for it, they all agree that the market has the potential to become, in LCS' words, "very large."
The firm will use the undisclosed amount to optimize the protocols for its genomic-selection application and to start building a sales and marketing force that "will become more visible in the second half of this year," CEO Fred Dom said.
Both companies are offering users of second-generation sequencing systems new tools to select portions of the genome for targeted resequencing but have optimized their products for different sequencing platforms.
Researchers from the Murdoch Childrens Research Institute in Parkville, Australia, investigated the feasibility of replacing "time-consuming, locus-specific testing for specific microdeletion and microduplication syndromes with microarray analysis." Study co-author Howard Slater spoke with BioArray News about the paper.